NEW YORK, June 25, 2026, 09:10 EDT
- Pfizer was indicated at $24.09 in premarket trading at 08:53 EDT after shares ended Wednesday off 2.75% at $24.04.
- Pfizer’s $0.43 quarterly dividend works out to a forward yield near 7.2% based on Wednesday’s close. The full-year payment will be about 57% to 61% of the company’s adjusted EPS target for 2026.
- FDA cleared wider use for Ibrance on Wednesday. That came two days after Pfizer reported its lung-cancer ADC did not meet its main survival goal.
- The setup is key with Pfizer, as its income story is getting stronger but the outlook for its newer oncology growth is still uneven.
Pfizer Inc. NYSE:PFE opens Thursday carrying a clearer income pitch, but growth looks shaky. Shares have slid, sending the dividend yield above 7%. The company scored an FDA win for Ibrance, its established breast cancer drug. But sigvotatug vedotin, a lung cancer antibody-drug conjugate from the Seagen deal, failed in late-stage testing.
U.S. markets weren’t open yet in New York. NYSE starts core trading at 9:30 a.m. ET until 4 p.m. ET, and June 25 isn’t listed as a 2026 holiday on the exchange. Pfizer last traded at $24.09 in premarket at 08:53 EDT, compared to Wednesday’s close of $24.04.
Pfizer’s (PFE) board set its third-quarter cash dividend at $0.43 a share, with the payout scheduled for Sept. 1 to shareholders of record as of July 24. On an annual basis, that’s $1.72 a share, giving a yield of 7.15% based on the latest close. The company’s 2026 adjusted diluted EPS guidance is $2.80 to $3.00, which puts the payout ratio in the range of 57% to 61%. Some investors may still be overlooking the gap between the dividend and the earnings outlook.
The gap is up because of price pressure on the stock, not from a hike in the dividend. Pfizer said its third-quarter payout will mark 351 straight quarterly dividends. The company said it still plans to keep and over time grow the dividend.
Pfizer’s decline has come on heavy trading. The stock dropped 7.3% from $25.92 at the close on June 17 to $24.04 at the June 24 close. From June 22 to June 24, volume hit about 196.6 million shares—more than six times what traded on June 17.
FDA approves Ibrance with trastuzumab, endocrine therapy for HR+/HER2+ breast cancer The FDA late clinical week gave the green light to Ibrance (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy as maintenance for adults dealing with HR-positive, HER2-positive locally advanced or metastatic breast cancer after induction therapy. Data from the PATINA trial, with 518 patients, showed the combo cut the risk of progression or death, hazard ratio 0.76. Overall survival numbers weren’t mature at the time of approval.
Pfizer’s chief U.S. commercial officer Aamir Malik said Ibrance is now the “first and only CDK4/6 inhibitor” approved for HR-positive metastatic breast cancer patients, no matter the HER2 status. Otto Metzger, principal investigator for the trial at Dana-Farber Cancer Institute, said resistance to dual anti-HER2 and endocrine therapy is “a central clinical challenge.” Pfizer
Pfizer said Monday its drug sigvotatug vedotin missed the main survival goal in a Phase 3 trial for previously treated metastatic non-squamous non-small cell lung cancer. The study didn’t find a statistically significant overall survival benefit over docetaxel. Reuters noted Pfizer got the asset when it bought Seagen in a $43 billion deal.
Pfizer’s chief oncology officer Jeff Legos said there’s “more work to be done” in advanced NSCLC where patients have already been treated. Pfizer said its drug showed a stronger trend among patients who had just one prior systemic therapy. The company plans to continue studying the drug in combinations, including testing it with pembrolizumab in first-line NSCLC. Pfizer
The split is the reason yield stands out right now. Pfizer says it expects 2026 revenue between $59.5 billion and $62.5 billion, and adjusted EPS in the $2.80 to $3.00 range. COVID-19 product revenue is set to drop about $1.5 billion from 2025, and the company is guiding to another $1.5 billion hit from losing exclusivity on some products.
Pfizer picked up Seagen’s targeted cancer treatments to counter weaker COVID-19 sales and more generics taking share from its lead drugs, Reuters said. Ibrance got approved, which backs the main franchise, but sigvotatug didn’t hit the main target—so the high-risk ADC part still needs more proof.
Pfizer is set for its next company update Aug. 4. The drugmaker will release its Q2 2026 results and host an analyst call at 10 a.m. EDT.
Related articles: NYSE:PFE
